Mayo Clinic: Cardiopoietic 'smart' stem cells show promise in heart failure patients

First-in-humans study introduces next generation cell therapy

2013-04-10

(Press-News.org) ROCHESTER, Minn. -- Translating a Mayo Clinic stem-cell discovery, an international team has demonstrated that therapy with cardiopoietic (cardiogenically-instructed) or "smart" stem cells can improve heart health for people suffering from heart failure. This is the first application in patients of lineage-guided stem cells for targeted regeneration of a failing organ, paving the way to development of next generation regenerative medicine solutions. Results of the clinical trial appear online of the Journal of the American College of Cardiology.

The multi-center, randomized Cardiopoietic stem cell therapy in heart failure (C-CURE) trial involved heart failure patients from Belgium, Switzerland and Serbia. Patients in the control group received standard care for heart failure in accordance with established guidelines. Patients in the cell therapy arm received, in addition to standard care, cardiopoietic stem cells -- a first-in-class biotherapeutic. In this process, bone marrow was harvested from the top of the patient's hip, and isolated stem cells were treated with a protein cocktail to replicate natural cues of heart development. Derived cardiopoietic stem cells were then injected into the patient's heart.

"The cells underwent an innovative treatment to optimize their repair capacity," says Andre Terzic, M.D., Ph.D., study senior author and director of the Mayo Clinic Center for Regenerative Medicine. "This study helps us move beyond the science fiction notion of stem cell research, providing clinical evidence for a new approach in cardiovascular regenerative medicine."

Every patient in the stem cell treatment group improved. Heart pumping function improved in each patient within six months following cardiopoietic stem cell treatment. In addition, patients experienced improved fitness and were able to walk longer distances than before stem cell therapy. "The benefit to patients who received cardiopoietic stem cell therapy was significant," Dr. Terzic says.

In an accompanying editorial, Charles Murry, M.D., Ph.D., and colleagues at the University of Washington, Seattle, say, "Six months after treatment, the cell therapy group had a 7 percent absolute improvement in EF (ejection fraction) over baseline, versus a non-significant change in the control group. This improvement in EF is dramatic, particularly given the duration between the ischemic injury and cell therapy. It compares favorably with our most potent therapies in heart failure."

The science supporting this trial is a product of a decade-long journey in decoding principles of stem cell-based heart repair. "Discovery of rare stem cells that could inherently promote heart regeneration provided a critical clue. In following this natural blueprint, we further developed the know-how needed to convert patient-derived stem cells into cells that can reliably repair a failing heart," says Dr. Terzic, underscoring the team effort in this endeavor.

Initial discovery led to the identification of hundreds of proteins involved in cardiogenesis, or the heart development process. The research team then identified which proteins are necessary in helping a stem cell become a reparative cell type, leading to development of a protein cocktail-based procedure that orients stem cells for heart repair. Such upgraded stem cells are called cardiopoietic or heart creative.

### Mayo Clinic partnered with Cardio3 Biosciences, a bioscience company in Mont-Saint-Guibert, Belgium, for advanced product development, manufacturing scale-up, and clinical trial execution.

Mayo Clinic and Dr. Terzic have a financial interest related to technology in this research program.

Contact: Traci Klein
507-284-2511 (evenings) VIDEO ALERT: Audio and video resources are available on the Mayo Clinic News Network.

About Mayo Clinic Mayo Clinic is a nonprofit worldwide leader in medical care, research and education for people from all walks of life. For more information, visit http://www.mayoclinic.org/about and http://www.mayoclinic.org/news.

Journalists can become a member of the Mayo Clinic News Network for the latest health, science and research news and access to video, audio, text and graphic elements that can be downloaded or embedded. END

ELSE PRESS RELEASES FROM THIS DATE:

Researchers identify critical metabolic alterations in triple-negative breast cancer cells

2013-04-10

WASHINGTON, DC (April 9, 2013)—Researchers at Fox Chase Cancer Center have identified a host of small molecules critical to metabolism in cells of triple-negative breast cancer—one of the least understood groups of breast cancer. These molecules, called metabolites, include key players in energy regulation and lipid synthesis. They could help pave the way for helping researchers differentiate among different forms of the disease and ultimately point to new targets for treatment. Jeffrey Peterson, PhD, a cancer biologist at Fox Chase, led the new studies, which also included ...

New technology spots drugs' early impact on cancer

2013-04-10

WASHINGTON, DC (April 9, 2013)—A new preclinical technology enables researchers to quickly determine if a particular treatment is effective against gastrointestinal stromal tumors (GISTs), providing a boost to animal research and possibly patient care, according to new findings presented by Fox Chase Cancer Center at the AACR Annual Meeting 2013 on Tuesday, April 9. The advantage of the tool, explains study author Lori Rink, PhD, assistant research professor at Fox Chase, is that it tells researchers if a particular compound is killing tumor cells in mice as early as ...

Research suggests new approach for spinal muscular atrophy

2013-04-10

PROVIDENCE, R.I. [Brown University] — There is no specific drug to treat spinal muscular atrophy (SMA), a family of motor neuron diseases that in its most severe form is the leading genetic cause of infant death in the United States and affects one in 6,000 people overall. But a new multispecies study involving a drug that treats amyotrophic lateral sclerosis (ALS) has pinpointed a mechanism of SMA that drug developers might be able to exploit for a new therapy. The research, published in the Journal of Neuroscience, reports that the drug Riluzole advanced neural cell ...

Manipulating calcium accumulation in blood vessels may provide a new way to treat heart disease

2013-04-10

Hardening of the arteries, or atherosclerosis, is the primary cause of heart disease. It is caused by calcium accumulation in the blood vessels, which leads to arteries becoming narrow and stiff, obstructing blood flow and leading to heart complications. Although many risk factors for atherosclerosis have been identified, the cause is not known and there is currently no way to reverse it once it sets in. In a new study published 9th April in the open access journal PLOS Biology, researchers have characterized the cells responsible for driving this calcium build-up in vessel ...

Bean leaves can trap bedbugs, researchers find

2013-04-10

Irvine, Calif. – Inspired by a traditional Balkan bedbug remedy, researchers have documented how microscopic hairs on kidney bean leaves effectively stab and trap the biting insects, according to findings published online today in the Journal of the Royal Society Interface. Scientists at UC Irvine and the University of Kentucky are now developing materials that mimic the geometry of the leaves. Bedbugs have made a dramatic comeback in the U.S. in recent years, infesting everything from homes and hotels to schools, movie theaters and hospitals. Although not known to transmit ...

New gene associated with almost doubled Alzheimer's risk in African-Americans

2013-04-10

NEW YORK – African-Americans with a variant of the ABCA7 gene have almost double the risk of developing late-onset Alzheimer's disease compared with African-Americans who lack the variant. The largest genome-wide search for Alzheimer's genes in the African-American community, the study was undertaken by the Alzheimer's Disease Genetics Consortium and led by neurologists from Columbia University Medical Center. It will be published in the April 10 issue of the Journal of the American Medical Association. The study was primarily funded by the National Institutes of Health ...

Genes linked with AD among African-Americans and individuals of European ancestry

2013-04-10

In a meta-analysis of data from nearly 6,000 African Americans, Alzheimer disease was significantly associated with a gene that have been weakly associated with Alzheimer disease in individuals of European ancestry, although additional studies are needed to determine risk estimates specific for African Americans, according to a study in the April 10 issue of JAMA, a Genomics theme issue. "Late-onset Alzheimer disease (LOAD) is the most common cause of dementia, increasing in frequency from 1 percent at age 65 years to more than 30 percent for people older than 80 years," ...

Genomics may help ID organisms in outbreaks of serious infectious disease

2013-04-10

Researchers have been able to reconstruct the genome sequence of an outbreak strain of Shiga-toxigenic Escherichia coli (STEC) using metagenomics (the direct sequencing of DNA extracted from microbiologically complex samples), according to a study in the April 10 issue of JAMA, a Genomics theme issue. The findings highlight the potential of this approach to identify and characterize bacterial pathogens directly from clinical specimens without laboratory culture. "The outbreak of Shiga-toxigenic Escherichia coli, which struck Germany in May-June 2011, illustrated the ...

Genetic variants of heart disorder discovered in some cases of stillbirth

2013-04-10

In a molecular genetic evaluation involving 91 cases of intrauterine fetal death, mutations associated with susceptibility to long QT syndrome (LQTS; a heart disorder that increases the risk for an irregular heartbeat and other adverse events) were discovered in a small number of these cases, preliminary evidence that may provide insights into the mechanism of some intrauterine fetal deaths, according to a study in the April 10 issue of JAMA, a Genomics theme issue. "Intrauterine fetal death is a major public health problem. About 1 million fetal deaths occur in the ...

Association between genetic mutation and risk of death for patients with thyroid cancer

2013-04-10

Presence of the genetic mutation BRAF V600E was significantly associated with increased cancer-related death among patients with papillary thyroid cancer (PTC); however, because overall mortality in PTC is low and the association was not independent of tumor characteristics, how to use this information to manage mortality risk in patients with PTC is unclear, according to a study in the April 10 issue of JAMA, a Genomics theme issue. "Papillary thyroid cancer is the most common endocrine malignancy and accounts for 85 percent to 90 percent of all thyroid cancers," according ...

Mayo Clinic: Cardiopoietic 'smart' stem cells show promise in heart failure patients

ELSE PRESS RELEASES FROM THIS DATE:

LAST 30 PRESS RELEASES: